✨ Free AI Report
Immuneering Corporation: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Immuneering Corporation
Company Research

Immuneering Corporation: Business Overview, Financials & Competitive Analysis

Immuneering Corporation scores 6/10 on the AskCyborg Cyborg Score (Solid). Compelling Phase 2a pancreatic cancer efficacy data backed by AI platform offers differentiation, though clinical execution risk and capital needs warrant cautious positioning. Immuneering has received an average recommendation of 'Moderate Buy' from seven analysts, with five buy ratings, one strong buy, and one sell. The company has a market.

What is Immuneering Corporation's industry? Immuneering Corporation (immuneering.com) operates in Biopharmaceuticals / Clinical-Stage Oncology. AskCyborg classifies Immuneering Corporation under Biopharmaceuticals / Clinical-Stage Oncology in its company registry.

Immuneering is a late-stage clinical oncology company advancing Deep Cyclic MEK inhibition. The company leverages artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) pl...

6/ 10Solid

Cyborg Score thesis

Compelling Phase 2a pancreatic cancer efficacy data backed by AI platform offers differentiation, though clinical execution risk...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals / Clinical-Stage Oncology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Immuneering Corporation Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Immuneering Corporation

AskCyborg analysts argue the bull and bear cases for Immuneering Corporation across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Immuneering Corporation OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Immuneering Corporation Overview

Pro stress-test →

Immuneering is a late-stage clinical oncology company advancing Deep Cyclic MEK inhibition. The company leverages artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies.

Strategic Profile

Pro stress-test →

The lead product candidate IMM-1-104, a dual-MEK inhibitor, is in Phase 1/2a clinical trial for treating patients with cancer including pancreatic, melanoma, and non-small cell lung cancer caused by RAS and/or RAF mutations. Recent Phase 2a data announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib combined with mGnP.

Competitive Landscape

Pro stress-test →

Immuneering competes in the clinical-stage oncology space developing medicines for broad cancer populations. Key competitors include established biotech firms with RAS-focused programs (Rgenix, Revolution Medicines) and larger pharmaceutical companies with MEK inhibitor portfolios. Immuneering's AI-driven RABIT platform and exceptional pancreatic cancer data provide differentiation, though clinical validation and regulatory approval timelines remain competitive risks.

Industry Context

Immuneering Corporation operates in Biopharmaceuticals / Clinical-Stage Oncology.

Key facts

Founded: 2008 · Headquarters: Cambridge, MA · Employees: 66 · Market cap: $338.35M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Immuneering Corporation.

  • Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer with atebimetinib plus mGnP combination in Phase 2a
  • Uses proprietary RABIT platform leveraging artificial intelligence for drug design and optimization
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Upgraded to Strong Buy rating due to positive Phase 2a data for atebimetinib in first-line RAS-mutant pancreatic cancer
  • December 2025Announced updated Phase 2a trial data with 86% overall survival at 9 months in pancreatic cancer patients
  • +1 moreTrack every material event for Immuneering Corporation as it happens. Explore monitoring →
Get alerted when Immuneering Corporation has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

RAS-targeted therapiesRAS inhibitor platform for oncology→MEK inhibitorsEstablished MEK inhibitor development→AI-driven drug discoveryAI-powered oncology platform→

Compare Immuneering Corporation with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Immuneering Corporation operates in Biopharmaceuticals / Clinical-Stage Oncology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceuticals by Cyborg Score

Browse Biopharmaceuticals / Clinical-Stage Oncology research →
NEW · MCP server

Ask your AI assistant about Immuneering Corporation

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Immuneering Corporation and its top competitor on Cyborg Score”
“What did Immuneering Corporation do this quarter?”
“Is Immuneering Corporation a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Immuneering Corporation do?+
Immuneering is a late-stage clinical oncology company advancing Deep Cyclic MEK inhibition. The company leverages artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) pl...
What is Immuneering Corporation's Cyborg Score?+
Immuneering Corporation has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Immuneering Corporation's main competitors?+
Named competitors include RAS-targeted therapies, MEK inhibitors, AI-driven drug discovery. The full competitive landscape is in the AskCyborg report.
How can I get the full Immuneering Corporation research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Immuneering Corporation research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Immuneering Corporation over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Halozyme Therapeutics, Inc.8Vera Therapeutics, Inc.7AbbVie Inc.7Amneal Pharmaceuticals, Inc.7Arcutis Biotherapeutics, Inc.7BioArctic AB7Biogen Inc.7Bristol-Myers Squibb Company7Immix Biopharma, Inc.7Innovent Biologics, Inc.Top companies in Biopharmaceuticals by Cyborg Score